MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

V Woodcock; Mark Middleton; Christian Rolfo; Elena Elez; Sandra Van Schaeybroeck; Julien Taieb; Jennifer Houlden; Linda Collins; Sharon Love; C Roberts; Thierry Andre; Robert Jones; Mark Lawler; Federica Di Nicolantonio; Margaret Grayson; alberto Bardelli; Pierre Laurent=puig; gordon McGregor; Tim Maughan; Josef Tabernero; Marc Peeters; Richard Wilson

doi:10.1093/annonc/mdw370.28

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

V Woodcock, Mark Middleton, Christian Rolfo, Elena Elez, Sandra Van Schaeybroeck, Julien Taieb, Jennifer Houlden, Linda Collins, Sharon Love, C Roberts, Thierry Andre, Robert Jones, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, alberto Bardelli, Pierre Laurent=puig, gordon McGregor, Tim Maughan, Josef TaberneroMarc Peeters, Richard Wilson

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Original language	English
Title of host publication	MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
Publisher	National Cancer Research Institute
DOIs	https://doi.org/10.1093/annonc/mdw370.28
Publication status	Published - 11 Oct 2016

Access to Document

10.1093/annonc/mdw370.28Licence: Unspecified

Cite this

Woodcock, V., Middleton, M., Rolfo, C., Elez, E., Van Schaeybroeck, S., Taieb, J., Houlden, J., Collins, L., Love, S., Roberts, C., Andre, T., Jones, R., Lawler, M., Di Nicolantonio, F., Grayson, M., Bardelli, A., Laurent=puig, P., McGregor, G., Maughan, T., ... Wilson, R. (2016). MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. In MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours National Cancer Research Institute. https://doi.org/10.1093/annonc/mdw370.28

@inproceedings{30a2c2a1feae4d759d7912ddd52b43e5,

title = "MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours",

author = "V Woodcock and Mark Middleton and Christian Rolfo and Elena Elez and {Van Schaeybroeck}, Sandra and Julien Taieb and Jennifer Houlden and Linda Collins and Sharon Love and C Roberts and Thierry Andre and Robert Jones and Mark Lawler and {Di Nicolantonio}, Federica and Margaret Grayson and alberto Bardelli and Pierre Laurent=puig and gordon McGregor and Tim Maughan and Josef Tabernero and Marc Peeters and Richard Wilson",

year = "2016",

month = oct,

day = "11",

doi = "10.1093/annonc/mdw370.28",

language = "English",

booktitle = "MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours",

publisher = "National Cancer Research Institute",

}

Woodcock, V, Middleton, M, Rolfo, C, Elez, E, Van Schaeybroeck, S, Taieb, J, Houlden, J, Collins, L, Love, S, Roberts, C, Andre, T, Jones, R, Lawler, M, Di Nicolantonio, F, Grayson, M, Bardelli, A, Laurent=puig, P, McGregor, G, Maughan, T, Tabernero, J, Peeters, M & Wilson, R 2016, MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. in MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute. https://doi.org/10.1093/annonc/mdw370.28

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. / Woodcock, V; Middleton, Mark; Rolfo, Christian et al.

MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute, 2016.

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

TY - GEN

T1 - MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

AU - Woodcock, V

AU - Middleton, Mark

AU - Rolfo, Christian

AU - Elez, Elena

AU - Van Schaeybroeck, Sandra

AU - Taieb, Julien

AU - Houlden, Jennifer

AU - Collins, Linda

AU - Love, Sharon

AU - Roberts, C

AU - Andre, Thierry

AU - Jones, Robert

AU - Lawler, Mark

AU - Di Nicolantonio, Federica

AU - Grayson, Margaret

AU - Bardelli, alberto

AU - Laurent=puig, Pierre

AU - McGregor, gordon

AU - Maughan, Tim

AU - Tabernero, Josef

AU - Peeters, Marc

AU - Wilson, Richard

PY - 2016/10/11

Y1 - 2016/10/11

U2 - 10.1093/annonc/mdw370.28

DO - 10.1093/annonc/mdw370.28

M3 - Conference contribution

BT - MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

PB - National Cancer Research Institute

ER -

Woodcock V, Middleton M, Rolfo C, Elez E, Van Schaeybroeck S, Taieb J et al. MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. In MErCuRIC1: A Phase Ia study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. National Cancer Research Institute. 2016 doi: 10.1093/annonc/mdw370.28